In recent weeks, Ionis Pharmaceuticals reported several advances, including European Commission approval of Dawnzera for preventing hereditary angioedema attacks in patients aged 12 and older, ...

The EC’s approval was based on results from the phase 3 OASIS-HAE study. The study showed that an 80mg dose of Dawnzera every ...

The goal of acute treatment of an hereditary angioedema (HAE) attack is to reduce its duration and severity and thus limit its impact on the patient’s functional ability and prevent a potentially ...

Ionis IONS and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema ...

Otsuka’s Dawnzera is now approved in the EU to prevent hereditary angioedema attacks in patients 12 and older, offering a self-administered, RNA-targeted prophylactic treatment option.

Otsuka Pharmaceutical, which licensed the antisense oligonucleotide from Ionis, has rights to commercialize it in Europe and Asia.